Myriad Genetics Inc (MYGN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MYGN SEC filings page.
Myriad Genetics Inc (MYGN) reported $806.6M in revenue over the twelve months to Jun 30, 2026, down 3.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Myriad’s revenue and gross margin held steady, but operating losses and debt rose, making the business more reliant on financing.
Revenue was nearly flat and gross margin remained about70.0% from FY2024 to FY2025. Operating margin nevertheless fell from-14.7% to-47.0% , concentrating the deterioration below gross profit rather than in the reported direct-cost structure.
FY2025 operating cash flow was only
The balance-sheet base contracted: total assets fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Myriad Genetics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Myriad Genetics Inc has an operating margin of -47.0%, meaning the company loses $47 on every $100 of revenue. This results in a profitability score of 24/100. This is down from -14.7% the prior year.
Myriad Genetics Inc's revenue declined 1.6% year-over-year, from $837.6M to $824.5M. This contraction results in a growth score of 48/100.
Myriad Genetics Inc carries a low D/E ratio of 0.33, meaning only $0.33 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 68/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.49, Myriad Genetics Inc holds $2.49 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
Not available for Myriad Genetics Inc, and counted as zero in the overall score.
Myriad Genetics Inc posts a -99.5% return on equity (ROE), meaning it loses $99 for every $100 of shareholders' equity. This results in a returns score of 17/100. This is down from -18.1% the prior year.
Myriad Genetics Inc scores -1.82, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($401.7M) relative to total liabilities ($338.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Myriad Genetics Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Myriad Genetics Inc reported a net loss of $366.0M while generating $1.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Myriad Genetics Inc reported an operating loss of $387.2M against $10.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Myriad Genetics Inc generated $190.7M in revenue in Q2 2026. This represents a decrease of 10.5% from the same quarter a year earlier. Against the prior quarter it is down 4.8%.
Myriad Genetics Inc's EBITDA was -$26.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 91.6% from the same quarter a year earlier. Against the prior quarter it is down 44.5%.
Myriad Genetics Inc reported -$43.2M in net income in Q2 2026. This represents an increase of 86.9% from the same quarter a year earlier. Against the prior quarter it is down 26.7%.
Myriad Genetics Inc earned -$0.46 per diluted share (EPS) in Q2 2026. This represents an increase of 87.1% from the same quarter a year earlier. Against the prior quarter it is down 27.8%.
Cash & Balance Sheet
Myriad Genetics Inc held $115.2M in cash against $120.7M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Myriad Genetics Inc's gross margin was 66.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 4.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.1 percentage points.
Myriad Genetics Inc's operating margin was -20.4% in Q2 2026, reflecting core business profitability. Against the prior quarter it is down 5.1 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Myriad Genetics Inc's net profit margin was -22.7% in Q2 2026, showing the share of revenue converted to profit. Against the prior quarter it is down 5.6 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Myriad Genetics Inc's ROE was -14.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 70.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.1 percentage points.
Capital Allocation
Myriad Genetics Inc invested $25.0M in research and development in Q2 2026. This represents a decrease of 2.3% from the same quarter a year earlier. Against the prior quarter it is down 7.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
MYGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $190.7M-10.5% | $200.4M+2.3% | $209.8M-0.4% | $205.7M-3.6% | $213.1M+0.8% | $195.9M-3.1% | $210.6M+7.1% | $213.3M+11.2% |
| Cost of Revenue | $63.7M+3.9% | $62.8M+1.8% | $63.0M+5.5% | $61.9M-2.5% | $61.3M-4.8% | $61.7M-4.5% | $59.7M-3.1% | $63.5M+10.2% |
| Gross Profit | $127.0M-16.3% | $137.6M+2.5% | $146.8M-2.7% | $143.8M-4.0% | $151.8M+3.2% | $134.2M-2.5% | $150.9M+11.8% | $149.8M+11.5% |
| R&D Expenses | $25.0M-2.3% | $27.1M-1.5% | $25.5M-22.5% | $28.2M-1.1% | $25.6M-5.5% | $27.5M+10.4% | $32.9M+56.7% | $28.5M+18.8% |
| SG&A Expenses | $57.8M-13.5% | $62.2M-6.5% | $55.6M+137.4% | $67.9M-51.2% | $66.8M-53.9% | $66.5M-52.7% | -$148.7M-203.0% | $139.1M+2.2% |
| Operating Income | -$38.9M+88.2% | -$30.7M-5.9% | -$5.7M+85.4% | -$23.3M-16.5% | -$329.2M-801.9% | -$29.0M-3.9% | -$39.1M-24.5% | -$20.0M+66.7% |
| EBITDA | -$26.3M+91.6% | -$18.2M-24.7% | $6.6M+127.4% | -$10.6M-125.5% | -$314.9M-1378.4% | -$14.6M-19.7% | -$24.1M-47.9% | -$4.7M+89.8% |
| Interest Expense | $4.1M+173.3% | $4.1M+412.5% | $4.4M+528.6% | $3.8M+375.0% | $1.5M+87.5% | $800K+60.0% | $700K-22.2% | $800K-20.0% |
| Income Tax | $600K+700.0% | $0+100.0% | -$1.0M-130.3% | $1.2M+33.3% | -$100K+80.0% | -$29.3M-29400.0% | $3.3M+400.0% | $900K+800.0% |
| Net Income | -$43.2M+86.9% | -$34.1M-34000.0% | -$8.0M+81.0% | -$27.4M-24.0% | -$330.5M-800.5% | -$100K+99.6% | -$42.2M-36.6% | -$22.1M+63.9% |
| EPS (Basic) | -$0.46+87.1% | -$0.36 | -$0.07+85.1% | -$0.29-20.8% | -$3.57-770.7% | $0.00+100.0% | -$0.47-38.2% | -$0.24+68.0% |
| EPS (Diluted) | -$0.46+87.1% | -$0.36 | -$0.07+85.1% | -$0.29-20.8% | -$3.57-770.7% | $0.00+100.0% | -$0.47-38.2% | -$0.24+68.0% |
| Diluted Shares (Avg) | 95M+2.5% | 94M+2.5% | N/A | 93M+2.4% | 93M+2.1% | 91M+1.7% | N/A | 91M+11.0% |
MYGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $638.9M-5.7% | $673.7M-33.0% | $706.6M-31.2% | $728.1M-32.7% | $677.3M-37.6% | $1.0B-9.4% | $1.0B-10.4% | $1.1B-5.9% |
| Current Assets | $289.0M+1.7% | $312.8M+8.9% | $332.6M+11.6% | $344.8M+17.6% | $284.3M-2.5% | $287.2M-1.1% | $298.0M-5.0% | $293.2M+10.5% |
| Cash & Equivalents | $115.2M+54.8% | $124.4M+35.5% | $149.6M+46.1% | $145.4M+45.5% | $74.4M-19.5% | $91.8M-5.3% | $102.4M-22.5% | $99.9M+31.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% |
| Inventory | $30.6M+6.6% | $27.9M-1.4% | $30.6M+11.3% | $31.6M+20.6% | $28.7M+10.0% | $28.3M+15.0% | $27.5M+25.0% | $26.2M+4.4% |
| Accounts Receivable | $109.5M-20.1% | $123.8M+2.8% | $115.3M-4.9% | $118.0M-6.1% | $137.0M+16.3% | $120.4M+1.9% | $121.2M+6.0% | $125.7M+9.1% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $47.1M-8.7% | $47.1M-83.5% | $51.6M-82.0% | $51.6M-82.0% | $51.6M-82.0% | $286.3M-0.2% | $286.3M-0.4% | $286.3M-0.1% |
| Total Liabilities | $335.0M+15.8% | $336.3M+11.7% | $338.6M+3.7% | $355.3M+1.6% | $289.2M-16.1% | $301.2M-14.1% | $326.5M-10.1% | $349.6M-24.9% |
| Current Liabilities | $130.7M-34.6% | $130.2M-13.8% | $133.8M-18.5% | $148.0M-4.1% | $199.9M+34.3% | $151.1M+3.4% | $164.1M+5.3% | $154.3M-26.3% |
| Non-Current Liabilities | $204.3M+128.8% | $206.1M+37.3% | $204.8M+26.1% | $207.3M+6.1% | $89.3M-54.4% | $150.1M-26.6% | $162.4M-21.7% | $195.3M-23.8% |
| Long-Term Debt | $120.7M | $120.3M+102.9% | $119.9M+202.8% | $119.5M+206.4% | N/A | $59.3M+53.2% | $39.6M+2.9% | $39.0M+1.3% |
| Total Equity | $303.9M-21.7% | $337.4M-52.1% | $368.0M-47.5% | $372.8M-49.1% | $388.1M-47.6% | $704.9M-7.2% | $701.1M-10.5% | $731.7M+7.1% |
| Retained Earnings | -$1.2B-10.4% | -$1.2B-52.8% | -$1.1B-48.3% | -$1.1B-56.1% | -$1.1B-57.1% | -$756.9M-15.5% | -$756.8M-20.2% | -$714.3M-19.4% |
MYGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.3M+39.0% | -$15.7M+3.7% | $10.6M+60.6% | $21.1M+2914.3% | -$13.6M-623.1% | -$16.3M+12.4% | $6.6M+112.1% | $700K+103.2% |
| Depreciation & Amortization | $12.6M-11.9% | $12.5M-13.2% | $12.6M-14.9% | $12.7M-17.0% | $14.3M-5.9% | $14.4M-8.3% | $14.8M-2.0% | $15.3M+8.5% |
| Stock-Based Compensation | $7.2M-32.7% | $6.5M-31.6% | N/A | $12.2M-1.6% | $10.7M-26.2% | $9.5M-20.8% | N/A | $12.4M+6.9% |
| Investing Cash Flow | -$3.2M+53.6% | -$6.5M+21.7% | -$6.0M-1.7% | -$6.2M-182.7% | -$6.9M-7.8% | -$8.3M-16.9% | -$5.9M+50.8% | $7.5M+400.0% |
| Financing Cash Flow | $2.2M-15.4% | -$3.0M-122.1% | -$8.2M-490.5% | $56.2M+1912.9% | $2.6M+8.3% | $13.6M+254.5% | $2.1M-98.3% | -$3.1M-24.0% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
MYGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.6%-4.6pp | 68.7%+0.2pp | 70.0%-1.7pp | 69.9%-0.3pp | 71.2%+1.7pp | 68.5%+0.5pp | 71.7%+3.0pp | 70.2%+0.3pp |
| Operating Margin | -20.4% | -15.3%-0.5pp | -2.7%+15.8pp | -11.3%-2.0pp | -154.5% | -14.8%-1.0pp | -18.6%-2.6pp | -9.4%+21.9pp |
| Net Margin | -22.7% | -17.0%-17.0pp | -3.8%+16.2pp | -13.3%-3.0pp | -155.1% | -0.1%+12.8pp | -20.0%-4.3pp | -10.4%+21.6pp |
| Return on Equity | -14.2%+70.9pp | -10.1%-10.1pp | -2.2%+3.8pp | -7.3%-4.3pp | -85.2%-80.2pp | 0.0%+3.4pp | -6.0%-2.1pp | -3.0%+5.9pp |
| Return on Assets | -6.8%+42.0pp | -5.1%-5.0pp | -1.1%+3.0pp | -3.8%-1.7pp | -48.8%-45.4pp | 0.0%+2.3pp | -4.1%-1.4pp | -2.0%+3.3pp |
| Current Ratio | 2.21+0.8x | 2.40+0.5x | 2.49+0.7x | 2.33+0.4x | 1.42-0.5x | 1.90-0.1x | 1.82-0.2x | 1.90+0.6x |
| Debt-to-Equity | 0.40-0.3x | 0.36+0.3x | 0.33+0.3x | 0.32+0.3x | 0.75+0.7x | 0.080.0x | 0.060.0x | 0.050.0x |
| Asset Turnover | 0.300.0x | 0.30+0.1x | 0.30+0.1x | 0.28+0.1x | 0.31+0.1x | 0.190.0x | 0.200.0x | 0.200.0x |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Myriad Genetics Inc MYGN | FY2025 | $824.5M | -$366.0M | -44.4% | $401.7M | 38/100 |
| Fulgent Genetics, Inc. FLGT | FY2025 | $322.7M | -$60.5M | -18.8% | $598.2M | 44/100 |
| CareDx, Inc. CDNA | FY2025 | $379.8M | -$21.4M | -5.6% | $3.3B | 43/100 |
| Castle Biosciences, Inc. CSTL | FY2025 | $344.2M | -$24.2M | -7.0% | $1.1B | 61/100 |
| Personalis, Inc. PSNL | FY2025 | $69.6M | -$81.3M | N/A | $1.7B | 51/100 |
| NeoGenomics, Inc. NEO | FY2025 | $727.3M | -$108.0M | -14.8% | $2.1B | 51/100 |
Where Myriad Genetics Inc Ranks
Frequently Asked Questions
What is Myriad Genetics Inc's annual revenue?
Myriad Genetics Inc (MYGN) reported $824.5M in total revenue for fiscal year 2025. This represents a -1.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Myriad Genetics Inc's revenue growing?
Myriad Genetics Inc (MYGN) revenue declined by 1.6% year-over-year, from $837.6M to $824.5M in fiscal year 2025.
Is Myriad Genetics Inc profitable?
No, Myriad Genetics Inc (MYGN) reported a net income of -$366.0M in fiscal year 2025, with a net profit margin of -44.4%.
What is Myriad Genetics Inc's EBITDA?
Myriad Genetics Inc (MYGN) had EBITDA of -$333.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Myriad Genetics Inc have?
As of fiscal year 2025, Myriad Genetics Inc (MYGN) had $149.6M in cash and equivalents against $119.9M in long-term debt.
What is Myriad Genetics Inc's gross margin?
Myriad Genetics Inc (MYGN) had a gross margin of 69.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Myriad Genetics Inc's operating margin?
Myriad Genetics Inc (MYGN) had an operating margin of -47.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Myriad Genetics Inc's net profit margin?
Myriad Genetics Inc (MYGN) had a net profit margin of -44.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Myriad Genetics Inc's return on equity (ROE)?
Myriad Genetics Inc (MYGN) has a return on equity of -99.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Myriad Genetics Inc's operating cash flow?
Myriad Genetics Inc (MYGN) generated $1.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Myriad Genetics Inc's total assets?
Myriad Genetics Inc (MYGN) had $706.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Myriad Genetics Inc spend on research and development?
Myriad Genetics Inc (MYGN) invested $106.8M in research and development during fiscal year 2025.
What is Myriad Genetics Inc's current ratio?
Myriad Genetics Inc (MYGN) had a current ratio of 2.49 as of fiscal year 2025, which is generally considered healthy.
What is Myriad Genetics Inc's debt-to-equity ratio?
Myriad Genetics Inc (MYGN) had a debt-to-equity ratio of 0.33 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Myriad Genetics Inc's return on assets (ROA)?
Myriad Genetics Inc (MYGN) had a return on assets of -51.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Myriad Genetics Inc's P/E ratio?
Myriad Genetics Inc (MYGN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $401.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Myriad Genetics Inc's price-to-sales ratio?
Myriad Genetics Inc (MYGN) trades at 0.5x sales, its market capitalization divided by revenue of $806.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $401.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Myriad Genetics Inc's Altman Z-Score?
Myriad Genetics Inc (MYGN) has an Altman Z-Score of -1.82, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Myriad Genetics Inc's Piotroski F-Score?
Myriad Genetics Inc (MYGN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Myriad Genetics Inc's earnings high quality?
Myriad Genetics Inc (MYGN) reported a net loss of $366.0M while generating $1.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Myriad Genetics Inc cover its interest payments?
Myriad Genetics Inc (MYGN) reported an operating loss of $387.2M against $10.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Myriad Genetics Inc?
Myriad Genetics Inc (MYGN) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.